Page 167 - Binder2

over a finite window—potentially inducing long-term
tolerance with a limited course of treatment.

That’s a radical departure from traditional biologic
economics, which are often built around:

• Repeat infusions
• Chronic dosing
• Drug dependency, not drug independence

While that may sound financially limiting, COUR flips the
model:
Durability becomes the commercial differentiator.
Not a liability. Not a tradeoff.
A premium.

In a healthcare system moving toward value-based care and
outcome-based pricing, this positions COUR as a post-
volume biotech: one built to thrive in a world where payers
no longer tolerate waste.

A Future-Facing Financial Blueprint

COUR’s financial model reflects the exact themes this
chapter has explored:

• Immune instruction over suppression
• Durability over speed
• Alignment over attrition

And as the biologics industry begins to reckon with the cost
of tolerization, the COUR blueprint offers something few
others can:

165